Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439277 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
A Phase 3 study of Obesity and Weight Gain, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06439277: Recruiting Phase 3 study of Obesity and Weight Gain, sponsored by Eli Lilly and Company.
NCT06439277 is a Phase 3 study of Obesity and Weight Gain that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 300 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06439277, a Phase 3 study of Obesity and Weight Gain, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- Driscoll Children's Hospital - Corpus Christi
- Epic Medical Research - DeSoto - DeSoto
- Valley Institute of Research - Fort Worth - Fort Worth
- Consano Clinical Research, LLC - Shavano Park
- Texas Valley Clinical Research - Weslaco
Other
- Investigaciones Medicas Imoba Srl - Buenos Aires
- Centro de Investigaciones Metabólicas (CINME) - Buenos Aires
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada - Buenos Aires
- Fundación Respirar - Buenos Aires
- DIM Clínica Privada - Ramos Mejía
California
- Children's Hospital Los Angeles - Los Angeles
- Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology - Sacramento
New York
- UBMD Pediatrics - Buffalo
- SUNY Upstate Medical University - Syracuse
Delaware
- Nemours Children's Health - Delaware - Wilmington
Georgia
- CenExel iResearch, LLC - Decatur
Idaho
- Medical Research Partners - Ammon
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT06439277 shows while recruiting
NCT06439277 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06439277 names 20 study sites across 10 states, led by Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT06439277 about?
NCT06439277 is a clinical study titled "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)". The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may includ...
What is the current status of trial NCT06439277?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-06-03. Estimated completion is 2030-12.
What conditions does trial NCT06439277 study?
This clinical trial studies the following conditions: Obesity, Weight Gain.
What interventions are being tested in trial NCT06439277?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06439277?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06439277 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06439277's enrollment target sits among peer trials
300 217th of 1053 higher than 825 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI